Medication-related Osteonecrosis of the Jaw After Long-term Bisphosphonate Treatment in a Cat

Overview

Journal J Vet Intern Med

Specialties General Medicine
Veterinary Medicine

Date 2019 Jan 22

PMID 30663796

Citations 8

Authors

Melinda J Larson

Ashley B Oakes

Ember Epperson

Dennis J Chew

Affiliations

Soon will be listed here.

Abstract

A 12-year-old, neutered female, domestic medium hair cat was evaluated for a nonhealing, oral mucosal ulceration. The cat had a history of idiopathic hypercalcemia that had been treated with a bisphosphonate for 41 months. Oral examination identified exposed maxillary bone adjacent to a previous extraction site. Histopathology of the exposed bone and associated mucosa was most consistent with medication-related osteonecrosis of the jaw. Treatment involved both medical and surgical interventions. Oral mucosal healing occurred after 6 months of treatment.

Citing Articles

A retrospective case series on bisphosphonate related osteonecrosis of the jaw in 20 cats.

Hatunen S, Anderson J, Bell C, Campos H, Finkelman M, Shope B Front Vet Sci. 2024; 11:1436988.

PMID: 39247125 PMC: 11377274. DOI: 10.3389/fvets.2024.1436988.

Clodronate disodium does not produce measurable effects on bone metabolism in an exercising, juvenile, large animal model.

Vergara-Hernandez F, Nielsen B, Popovich Jr J, Panek C, Logan A, Robison C PLoS One. 2024; 19(4):e0300360.

PMID: 38626145 PMC: 11020481. DOI: 10.1371/journal.pone.0300360.

Ionized hypercalcemia can resolve with nutritional modification in cats with idiopathic hypercalcemia or chronic kidney disease.

Ehrlich M, Rudinsky A, Chew D, Parker V J Feline Med Surg. 2024; 26(2):1098612X241229811.

PMID: 38415620 PMC: 10911303. DOI: 10.1177/1098612X241229811.

Management of insufficiency fractures associated with long-term bisphosphonate therapy in a cat.

Meneghetti L, Perry K JFMS Open Rep. 2023; 9(2):20551169231183752.

PMID: 37581124 PMC: 10423456. DOI: 10.1177/20551169231183752.

Alendronate treatment in cats with persistent ionized hypercalcemia: A retrospective cohort study of 20 cases.

Kurtz M, Desquilbet L, Maire J, Da Riz F, Canonne-Guibert M, Benchekroun G J Vet Intern Med. 2022; 36(6):1921-1930.

PMID: 36181368 PMC: 9708413. DOI: 10.1111/jvim.16508.

References

Lundberg A, Roady P, Somrak A, Howes M, Fan T . Zoledronate-Associated Osteonecrosis of the Jaw in a Dog with Appendicular Osteosarcoma. J Vet Intern Med. 2016; 30(4):1235-40. PMC: 5089613. DOI: 10.1111/jvim.13980. View

Ruggiero S, Dodson T, Fantasia J, Goodday R, Aghaloo T, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72(10):1938-56. DOI: 10.1016/j.joms.2014.04.031. View

Hostutler R, Chew D, Jaeger J, Klein S, Henderson D, DiBartola S . Uses and effectiveness of pamidronate disodium for treatment of dogs and cats with hypercalcemia. J Vet Intern Med. 2005; 19(1):29-33. DOI: 10.1892/0891-6640(2005)19<29:uaeopd>2.0.co;2. View

Allen M, Burr D . Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg. 2008; 66(5):987-94. PMC: 2464292. DOI: 10.1016/j.joms.2008.01.038. View

Marx R, Sawatari Y, Fortin M, Broumand V . Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63(11):1567-75. DOI: 10.1016/j.joms.2005.07.010. View

Reszka A, Rodan G . Bisphosphonate mechanism of action. Curr Rheumatol Rep. 2003; 5(1):65-74. DOI: 10.1007/s11926-003-0085-6. View

Council N, Dyce J, Drost W, de Brito Galvao J, Rosol T, Chew D . Bilateral patellar fractures and increased cortical bone thickness associated with long-term oral alendronate treatment in a cat. JFMS Open Rep. 2017; 3(2):2055116917727137. PMC: 5580850. DOI: 10.1177/2055116917727137. View

Larson M, Oakes A, Epperson E, Chew D . Medication-related osteonecrosis of the jaw after long-term bisphosphonate treatment in a cat. J Vet Intern Med. 2019; 33(2):862-867. PMC: 6430911. DOI: 10.1111/jvim.15409. View

Landesberg R, Woo V, Cremers S, Cozin M, Marolt D, Vunjak-Novakovic G . Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci. 2011; 1218:62-79. PMC: 4477826. DOI: 10.1111/j.1749-6632.2010.05835.x. View

10.

Saad F, Brown J, Van Poznak C, Ibrahim T, Stemmer S, Stopeck A . Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2011; 23(5):1341-1347. DOI: 10.1093/annonc/mdr435. View

11.

Whitney J, Barrs V, Wilkinson M, Briscoe K, Beatty J . Use of bisphosphonates to treat severe idiopathic hypercalcaemia in a young Ragdoll cat. J Feline Med Surg. 2010; 13(2):129-34. PMC: 10822308. DOI: 10.1016/j.jfms.2010.09.011. View

12.

Allen M, Chu T, Ruggiero S . Absence of exposed bone following dental extraction in beagle dogs treated with 9 months of high-dose zoledronic acid combined with dexamethasone. J Oral Maxillofac Surg. 2013; 71(6):1017-26. PMC: 3644548. DOI: 10.1016/j.joms.2012.11.016. View

13.

Woo S, Hellstein J, Kalmar J . Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006; 144(10):753-61. DOI: 10.7326/0003-4819-144-10-200605160-00009. View

14.

Spugnini E, Vincenzi B, Caruso G, Baldi A, Citro G, Santini D . Zoledronic acid for the treatment of appendicular osteosarcoma in a dog. J Small Anim Pract. 2008; 50(1):44-6. DOI: 10.1111/j.1748-5827.2008.00635.x. View

15.

Khan A, Morrison A, Kendler D, Rizzoli R, Hanley D, Felsenberg D . Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J Clin Densitom. 2016; 20(1):8-24. DOI: 10.1016/j.jocd.2016.09.005. View

16.

Drake M, Clarke B, Khosla S . Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008; 83(9):1032-45. PMC: 2667901. DOI: 10.4065/83.9.1032. View

17.

Hoff A, Toth B, Altundag K, Johnson M, Warneke C, Hu M . Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008; 23(6):826-36. PMC: 2677083. DOI: 10.1359/jbmr.080205. View

18.

Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis C . Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009; 27(32):5356-62. DOI: 10.1200/JCO.2009.21.9584. View

19.

Marx R . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61(9):1115-7. DOI: 10.1016/s0278-2391(03)00720-1. View

20.

Fliefel R, Troltzsch M, Kuhnisch J, Ehrenfeld M, Otto S . Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg. 2015; 44(5):568-85. DOI: 10.1016/j.ijom.2015.01.026. View